4-Butyl-1,2-diphenyl-3,5-pyrazoli-dindion Chemische Eigenschaften,Einsatz,Produktion Methoden
R-S?tze Betriebsanweisung:
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
R20/21/22:Gesundheitssch?dlich beim Einatmen,Verschlucken und Berührung mit der Haut.
R42/43:Sensibilisierung durch Einatmen und Hautkontakt m?glich.
R45:Kann Krebs erzeugen.
S-S?tze Betriebsanweisung:
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn m?glich, dieses Etikett vorzeigen).
S22:Staub nicht einatmen.
S53:Exposition vermeiden - vor Gebrauch besondere Anweisungen einholen.
Beschreibung
Phenylbutazone, one of the earliest NSAIDs
introduced, is now indicated for the symptomatic
relief of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, gout, and
acute superficial thrombophlebitis. The gastrointestinal and bone marrow toxicity observed in its early use have been greatly
reduced by lower dosage (300 mg/d). Nevertheless, it is used primarily where other drugs have
failed and then only for short-term therapy. The
drug has a long serum half-life of about 100 h. It
is a moderately active cyclooxygenase inhibitor
and it suppresses both spontaneous and chemotactic motility of neutrophils. In addition to the
serious gastrointestinal and hematological adverse effects, sodium and water retention, rash,
vertigo, and dermatitis are observed.
Chemische Eigenschaften
Off-Whtie Solid
Verwenden
Phenylbutazone, a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of COX. Phenylbutazone-dependent inactivation of COX and prostacyclin synthase is markedly increased in the presence of 100 μM hydrogen peroxide with half-maximal effects at Phenylbutazone concentrations of 100 and 25 μM for COX and prostacyclin synthase, respectively.
Weltgesundheitsorganisation (WHO)
Phenylbutazone, a pyrazolone derivative with anti-inflammatory,
analgesic and antipyretic activity, was introduced in 1949 for the treatment of
rheumatic disorders. Its use was subsequently associated with serious and
sometimes fatal adverse reactions, notably cases of aplastic anaemia and
agranulocytosis. Many national drug regulatory authorities consider that more
recently introduced drugs offer a safer alternative for most, if not all, patients
requiring anti-inflammatory agents. Phenylbutazone has thus been either
withdrawn at the national level or retained with rigorously restricted indications for
patients unresponsive to other therapy. These restrictions also apply, in general, to
combination products containing phenylbutazone.
Allgemeine Beschreibung
Odorless white or off-white crystalline powder. Tasteless at first, but slightly bitter aftertaste. pH (aqueous solution) 8.2.
Air & Water Reaktionen
Phenylbutazone is relatively stable at ambient temperatures. Aqueous decomposition of Phenylbutazone occurs by hydrolysis and oxidation. Insoluble in water.
Reaktivit?t anzeigen
Phenylbutazone is incompatible with strong oxidizers, strong acids and strong bases. .
Brandgefahr
Flash point data for Phenylbutazone are not available; however, Phenylbutazone is probably combustible.
Sicherheitsprofil
Suspected human
carcinogen producing leukemia. A human
poison by parenteral route. An experimental poison by ingestion, intraperitoneal,
subcutaneous, intravenous, and
intramuscular routes. Human systemic
effects by ingestion and possibly other
routes: fever, blood pressure increase, other
unspecified vascular effects, damage to
kidney tubules and glomeruli, decreased
urine volume, blood in the urine, reduction
in the number of whte blood cells, and
agranulocytosis. Experimental teratogenic
and reproductive effects. Human mutation
data reported. An eye irritant. An antiinflammatory agent. When heated to
decomposition it emits toxic fumes of NOx
l?uterung methode
Crystallise the dione from EtOH. Its pK2 3 is 4.52 (in H2O), 4.89 (in 50% aqueous EtOH) and 5.25 (80% 2-methoxyethanol). It complexes with Hg2+, Cd2+ and Zn2+. It has UV with max at 239.5nm in MeOH+50% aqueous HClO4 and 264nm in aqueous 0.1N NaOH. [Beilstein 24 III/IV 1123.]
4-Butyl-1,2-diphenyl-3,5-pyrazoli-dindion Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte